Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
What Zai Lab’s latest oncology data reveal about its long-term positioning in ADC and immunotherapy markets
Zai Lab presents new oncology data at AACR 2026. Discover what its ADC and immunotherapy pipeline could mean for future cancer treatment strategies.
Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Why Biocytogen and Acepodia are betting on BsAD2Cs for next-gen cancer therapy
Biocytogen and Acepodia expand their ADC collaboration to evaluate dual-payload bispecifics. Find out how this model could reshape solid tumor therapy.
Amgen acquires Dark Blue Therapeutics to expand targeted AML degradation strategy
Amgen has acquired United Kingdom-based Dark Blue Therapeutics Ltd. in a deal valued at up to $840 million, adding a first-in-class preclinical asset to its early oncology pipeline. The investigational small molecule, designed to degrade MLLT1 and MLLT3 proteins, targets transcriptional dependencies in acute myeloid leukemia. With preclinical data suggesting anti-leukemic activity and mechanistic differentiation, […]